申请人:Sankyo Company, Limited
公开号:US06673804B1
公开(公告)日:2004-01-06
A compound of the formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof:
R1 is H or NHOH. R2 is H, optionally substituted alkyl, cycloalkyl or a group —AR6.
A is an alkylene which may be optionally interrupted by O, —S(O)m— or —N(R9). R6 is a group (II), (III), (IV)
X is O, S, —N(R10)—, —C(R11)(R12)—. Y is O, CO, —S(O)n—, —N(R10)—, —C(R11)(R12)—. Each of R7 and R8 is H, alkyl, COOH, optionally substituted alkyl, etc. Each of R9, R10, R11, and R12 is H, alkyl, etc. Each of m and n is 0 to 2. R3 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl. R4 is optionally substituted (hetero)arylene. R5 is optionally substituted alkyl, optionally substituted (hetero)aryl. These compounds have matrixmetalloproteinase—13 inhibitory activity and aglycanase inhibitory activity.
公式(I)的化合物或其药理学上可接受的盐、酯或其他衍生物:
R1为H或NHOH。R2为H,可选择地取代的烷基,环烷基或一种—AR6基团。
A为一种可以选择地被O、—S(O)m—或—N(R9)中断的烷基。R6为一种(II)、(III)、(IV)基团。
X为O、S、—N(R10)—、—C(R11)(R12)—。Y为O、CO、—S(O)n—、—N(R10)—、—C(R11)(R12)—。R7和R8中的每一个为H、烷基、COOH、可选择地取代的烷基等。R9、R10、R11和R12中的每一个为H、烷基等。m和n中的每一个为0到2。R3为H、可选择地取代的烷基、可选择地取代的环烷基、可选择地取代的烯基、可选择地取代的炔基。R4为可选择地取代的(杂)芳基。R5为可选择地取代的烷基、可选择地取代的(杂)芳基。这些化合物具有基质金属蛋白酶-13抑制活性和糖基酶抑制活性。